Abbvie seeks to add major depressive disorder to drug label
Abbvie has filed a supplemental marketing authorization application with the FDA to expand the indication of cariprazine to include major depressive disorder.
by Marketwire, translated by daniel pedersen
On Wednesday, US-based Abbvie has filed a supplemental drug application with the US Food and Drug Administration (FDA) to have cariprazine approved for the adjunctive treatment of major depressive disorder (MDD), a company press release reports.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck preps for war against generic drugmakers in US
For subscribers
.jpg&w=384&q=75)
